{"schema_version":"1.0","type":"article","title":"The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk?","url":"https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.md","lang":"en","date":"2026-06-22","publish_at":"2026-06-22T08:49:01+08:00","updated_at":"2026-06-22","category":"商業分析系列","topic":"商業分析系列","tags":["Obesity medicine","GLP-1","Eli Lilly","Novo Nordisk","Pfizer","Roche","AstraZeneca","Regeneron","Biotech investing","Capital markets"],"summary":"Lilly and Novo Nordisk dominate the first phase of the obesity-drug market. The next investment question is who can become the third major player by solving the problems GLP-1 leaders have not fully solved.","key_points":[],"facts":[],"sections":["1. The Duopoly Is Moving Beyond Injections: Oral Drugs and Multi-Target Biology Are the Next Battlefield","2. The Third Player Cannot Be a Weaker Lilly or Novo","3. Pfizer: Berobenatide and the Monthly-Injection Window","4. Roche: Petrelintide for Tolerability, Enicepatide for Efficacy","5. AstraZeneca: Elecoglipron Is About the Cardio-Renal-Metabolic Matrix","6. Regeneron: Solving What GLP-1 Does Not Solve - Muscle Loss","7. China and Asia Are No Longer Just Followers","Conclusion: The Next Obesity-Drug War Is Not About Finding Another Tirzepatide"],"references":[],"images":[{"alt":"Product-portfolio battle","url":"https://drugnews.com.tw/assets/articles/obesity-drug-third-place-competition-en/figure-01.png"},{"alt":"A third player needs asymmetry","url":"https://drugnews.com.tw/assets/articles/obesity-drug-third-place-competition-en/figure-02.png"},{"alt":"Pfizer's opening","url":"https://drugnews.com.tw/assets/articles/obesity-drug-third-place-competition-en/figure-03.png"},{"alt":"Roche's two-axis strategy","url":"https://drugnews.com.tw/assets/articles/obesity-drug-third-place-competition-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/obesity-drug-third-place-competition-en/cover-generated.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-22）。The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk?。https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-06-22-obesity-drug-third-place-competition.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}